GILD Stock Rose 5.68%, Gilead Reports 'Positive Data' on Treating COVID-19 with Remdesivir

All content provided by the site, hyperlinks, related applications, forums, blogs, social networks and other information is taken from third-party sources and is intended for reference only. We make no warranties with respect to our content, including but not limited to accuracy and timeliness. No part of the content we provide is financial advice, legal advice or any other form of advice intended for any of your personal purpose. Any use of our content is entirely at your own risk. You should conduct your own research, review, analysis and verification of our content before relying on them. Trading is a very risky activity that can lead to large losses, so consult your financial Advisor before making any decision. No content on our site is a public offer or invitation to action.